Axelyf Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $2.63M

  • Investors
  • 4

Axelyf General Information

Description

Operator of a drug development company intended for metabolic diseases. The company utilizes a proprietary lipid nanoparticle delivery platform and an AI model for lipid design to advance drug candidates, including in vivo CAR-T programs for solid tumors and treatments for autoimmune hepatitis, enabling healthcare providers to address complex diseases where conventional medical approaches have been insufficient

Contact Information

Website
www.axelyf.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 33 Glenland Road
  • Unit 2
  • Chestnut Hill, MA 02467
  • United States
+1 (508)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 33 Glenland Road
  • Unit 2
  • Chestnut Hill, MA 02467
  • United States
+1 (508)

Axelyf Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axelyf Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 13-Oct-2026 $2.63M Completed Pre-Clinical Trials
2. Seed Round 29-Aug-2025 Completed Pre-Clinical Trials
1. Seed Round 02-Nov-2022 $1.2M $1.2M Completed Pre-Clinical Trials
To view Axelyf’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Axelyf Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axelyf Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
76Bio VC-Backed Company Minority
Omega ehf Venture Capital Minority
Silfurberg (Reykjavík) Venture Capital Minority
Brunnur Ventures Venture Capital Minority
To view Axelyf’s complete investors history, request access »

Axelyf Investments (1)

Axelyf’s most recent deal was a Corporate Asset Purchase with 76Bio (A Portfolio of Integrated Lipid Library Assets). The deal was made on 01-Aug-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
76Bio (A Portfolio of Integrated Lipid Library Assets) 01-Aug-2024 Corporate Asset Purchase Buildings and Property
To view Axelyf’s complete investments history, request access »

Axelyf FAQs

  • When was Axelyf founded?

    Axelyf was founded in 2022.

  • Where is Axelyf headquartered?

    Axelyf is headquartered in Chestnut Hill, MA.

  • What is the size of Axelyf?

    Axelyf has 10 total employees.

  • What industry is Axelyf in?

    Axelyf’s primary industry is Drug Discovery.

  • Is Axelyf a private or public company?

    Axelyf is a Private company.

  • What is Axelyf’s current revenue?

    The current revenue for Axelyf is .

  • How much funding has Axelyf raised over time?

    Axelyf has raised $7.13M.

  • Who are Axelyf’s investors?

    76Bio, Omega ehf, Silfurberg (Reykjavík), and Brunnur Ventures have invested in Axelyf.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process